KLK3 and Familial prostate cancer: The research team redefined the event-free survival, as the time from randomization until the first evidence of either biochemical progression, clinical or radiological progression, initiation of a non-trial treatment death from prostate cancer or PSA level of at least 2 ng/ml at any time after randomization.